Your shopping cart is currently empty

Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $36 | In Stock | In Stock | |
| 2 mg | $52 | In Stock | In Stock | |
| 5 mg | $85 | In Stock | In Stock | |
| 10 mg | $143 | In Stock | In Stock | |
| 25 mg | $283 | In Stock | In Stock | |
| 50 mg | $477 | In Stock | In Stock | |
| 100 mg | $698 | In Stock | - | |
| 500 mg | $1,470 | Inquiry | Inquiry |
| Description | Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. |
| Targets&IC50 | Thrombin:9.3 nM |
| In vitro | Dabigatran is a very potent anticoagulant. Dabigatran shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of activity. Dabigatran inhibits thrombin, plasmin, factor Xa, trypsin, tPA and activated protein C with Ki of 4.5 nM, 1.7 μM, 3.8 μM, 50 nM, 45 μM and 20 μM, respectively. [1] Dabigatran specifically and reversibly inhibits thrombin. [2] |
| In vivo | Dabigatran exhibits the most favorable activity profile following i.v. administration to rats. [1] The bioavailability of dabigatran after p.o. administration of dabigatran etexilate is 7.2%. Dabigatran is predominantly excreted in the feces after p.o. treatment and in the urine after i.v. treatment. The mean terminal half-life of dabigatran is approximately 8 hours. Dabigatran acylglucuronides accounts for 0.4% and 4% of the dose in urine after p.o. and i.v. dosing, respectively. [3] |
| Synonyms | BIBR 953ZW, BIBR 953 |
| Molecular Weight | 471.51 |
| Formula | C25H25N7O3 |
| Cas No. | 211914-51-1 |
| Smiles | Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | 0.1M HCL: 20.6 mg/mL (43.69 mM) DMSO: < 1 mg/mL (insoluble or slightly soluble) H2O: < 0.1 mg/mL (insoluble) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
0.1M HCL
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.